Results 291 to 300 of about 299,603 (337)

Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT2BR) in murine models and ex vivo models of scleroderma skin

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case‐specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options.
Thuong Trinh‐Minh   +12 more
wiley   +1 more source

Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography

open access: yesArthritis &Rheumatology, EarlyView.
Objective This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high‐resolution peripheral quantitative computed tomography (HR‐pQCT). Methods This was a phase 4, double‐blind, randomized, placebo‐controlled trial.
Yingzhao Jin   +11 more
wiley   +1 more source

Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA)–associated anticitrullinated protein antibodies (ACPAs) target various antigens by binding short citrulline amino acid motifs, resulting in heterogeneous ACPA profiles among patients. Here we analyzed ACPA patterns by recognized citrulline motifs in relation to the RA risk factors HLA‐DRB1 shared epitope (SE) alleles
Linda Mathsson Alm   +18 more
wiley   +1 more source

Regulation of Chondrocyte Metabolism and Osteoarthritis Development by Sirt5 Through Protein Lysine Malonylation

open access: yesArthritis &Rheumatology, EarlyView.
Objective Chondrocytemetabolic dysfunction plays an important role in osteoarthritis (OA) development during aging and obesity. Protein posttranslational modifications (PTMs) have recently emerged as an important regulator of cellular metabolism. We aim to study one type of PTM, lysine malonylation (MaK), and its regulator sirtuin 5 (Sirt5) in OA ...
Huanhuan Liu   +11 more
wiley   +1 more source

Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk. Methods We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis.
Achille Marino   +31 more
wiley   +1 more source

Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

open access: yesArthritis &Rheumatology, EarlyView.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim   +5 more
wiley   +1 more source

The Inflation Reduction Act and Etanercept

open access: yes
Arthritis &Rheumatology, EarlyView.
Charles L. Bennett   +6 more
wiley   +1 more source

Drug Allergy [PDF]

open access: yesPrimary Care: Clinics in Office Practice, 2016
An adverse drug reaction relates to an undesired response to administration of a drug. Type A reactions are common and are predictable to administration, dose response, or interaction with other medications. Type B reactions are uncommon with occurrences that are not predictable.
Abdul, Waheed   +2 more
core   +5 more sources

Home - About - Disclaimer - Privacy